Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Resumen
Palabras clave
Anticuerpos; Inmunoterapia; Cáncer de cabeza y cuello
Citación recomendada
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019 Jan;107:142–52.
Audiencia
Professionals
Usar este identificador para citar y/o enlazar este documento
https://hdl.handle.net/11351/5761Este elemento aparece en las siguientes colecciones
- HVH - Articles científics [2970]
- VHIO - Articles científics [864]
El ítem tiene asociados los siguientes ficheros de licencia: